HT
PTCT icon

Headlands Technologies’s PTC Therapeutics PTCT Stock Holding History

Headlands Technologies’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4,591
Closed -$349K – 923
2025
Q4 		$349K Buy
+4,591
New +$334K 0.03% 482
2025
Q3 		– Sell
-9,269
Closed -$453K – 1120
2025
Q2 		$453K Buy
+9,269
New +$440K 0.05% 320
2025
Q1 		– Sell
-7,228
Closed -$326K – 1441
2024
Q4 		$326K Buy
7,228
+6,462
+844% +$277K 0.03% 430
2024
Q3 		$28.4K Sell
766
-5,845
-88% -$196K ﹤0.01% 899
2024
Q2 		$202K Buy
6,611
+3,002
+83% +$97.2K 0.02% 474
2024
Q1 		$105K Sell
3,609
-1,075
-23% -$30.1K 0.03% 534
2023
Q4 		$129K Buy
4,684
+3,338
+248% +$76.3K 0.04% 346
2023
Q3 		$30.2K Sell
1,346
-750
-36% -$27.9K 0.01% 526
2023
Q2 		$85.2K Buy
+2,096
New +$103K 0.03% 409

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Headlands Technologies's PTCT Position: Q1 2026 in Review

Headlands Technologies sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 4,591 shares — an estimated $349K sold.

Headlands Technologies first reported a position in PTCT in Q2 2023 and held it in 9 quarters. The position peaked at $453K in Q2 2025. 352 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Headlands Technologies reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 4,591 PTC Therapeutics shares in Q1 2026, an estimated $349K.
  • Headlands Technologies first reported a position in PTC Therapeutics in Q2 2023 and held it in 9 quarters.
  • Headlands Technologies's PTC Therapeutics position peaked at $453K in Q2 2025.
  • 352 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.